Physician profile
Michael Alan Caplan
NPI 1275572562
$13,416.57
in general payments reported to CMS, 2019-2025
54 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,988 · 2020: $1,497 · 2021: $1,393 · 2022: $1,017 · 2023: $715 · 2024: $687 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.58 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $5,617.25 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $806.91 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $667.31 | 2019-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $600.24 | 2019-2022 | |
| Pfizer INC. | $536.33 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $448.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $385.37 | 2019-2024 | Trelegy Ellipta |
| Allergan, INC. | $381.74 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.07 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $352.73 | 2019-2024 | Jardiance, Zepbound, Emgality |
| Amarin Pharma, INC. | $312.17 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $269.32 | 2022-2024 | |
| Abbvie INC. | $230.12 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $225.56 | 2019-2024 | Capvaxive |
| Corcept Therapeutics | $194.90 | 2024-2025 | Korlym |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Caplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.